MIRA INFORM REPORT

 

 

Report Date :

13.08.2012

                                    

IDENTIFICATION DETAILS

 

Name :

CI FARMACAPSULAS SA

 

 

Registered Office :

Calle 79B Nro. 78C-21, Barranquilla, Atlantico 080100

 

 

Country :

Columbia

 

 

Year of Establishment :

1985

 

 

Legal Form :

Sociedad Anonima

 

 

Line of Business :

Manufacturer of pharmaceutical capsules

 

 

No. of Employees :

600

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 


NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Columbia

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

GEOPOLITICS

 

POLITICAL DATA

ECONOMIC DATA

Form of Government: Republic


Economic Risk: Low

Currency: 1.00 COP = 0.000557880 USD

Branch Situation: Stable

 

 

IDENTIFICATION

 

Legal Name:

CI FARMACAPSULAS SA

 

 

Legal Address

Calle 79B Nro. 78C-21, Barranquilla, Atlantico 080100, Colombia

Operative Address

Calle 79B Nro. 78C-21, Barranquilla, Atlantico 080100, Colombia

Telephone:

+57 (5) 330-4100

NIT :

 890105927

Fax:

+57 (5) 330-4197

Legal Form:

Sociedad Anonima

Email:

lledesma@farmacapsulas.com

Registered in:

Colombia

Website:

http://www.farmacapsulas.com/

Date Created:

1985

Manager:

Saul Gilinski, Chairman

Date Incorporated:

May 13th 1975

Staff:

600

Stock:

NA

 

 

Value:

NA

Activity:

Manufacturer of pharmaceutical capsules.

 

 

BANKS

 

Name of the Bank

Bancolombia

 

 

BUSINESS

 

HISTORY

 

The company was created in 1985.

PRINCIPAL ACTIVITY

 

C.I. Farmacapsulas S.A. manufactures gelatin and vegetable-derived two-piece capsules for pharmaceutical and health nutrition companies in Colombia and internationally.

Products/Services description:

 

The company also offers contract manufacturing services for pharmaceutical oral dosage forms, including modified release pellets, liquid-filled capsules, tablets, suspensions, non effervescent powder, liquids, and two pieces capsules. It develops and manufactures oral pharmaceuticals.

Sales are:

 

Wholesale

Clients:

 

Pharmaceutical and health nutrition companies.

Operations area:

 

National, International, Local

The company imports from depending on demand

The company exports to Perú, Bolivia, Chile, Argentina, Paraguay, Brazil, Venezuela, Central America and USA

Trade References:

 

The person contacted refused to provide the names of their suppliers for us to check the trade references.

 

The subject employs 600 employee(s)

Comments on staff:

 

This information could not be confirmed by the staff.

 

 

 

PAYMENTS

 

regular

LOCATION

Headquarters

 

The company is headquartered at Calle 79B Nro. 78C-21, Barranquilla, Atlantico 080100, Colombia.

 

 

Shareholders

- Manager - Related Companies

 

Listed at the stock exchange:

 

NO

Shareholders Parent Company(ies):

 

This is a private company. Despite our long searches we could not confirm the current shareholders.

Management:

 

Saul Gilinski, Chairman, Legal representative

Florette Mendal De Gilinski, Deputy Legal representative (1st)

Gloria Eugenia Henao Jinete, Deputy Legal representative (2nd)

Luis Alberto Ledesma Angulo, Accountant

 

 

 

Financials


- COMMERCIAL TRENDS AND FORECAST

As a private company the subject does not publish any financial statements.

We have contacted the company but we were unable to speak with a representative.

However our financial sources could provide us with the following data.

 

Those figures are estimates provided by confidential banking and financial institutions working with the company.

 

 

Currency

DATE

COP

2011

Turnover

93,147,133,000

Operating Income

4,033,821,000

Net Income

3,530,992,000

Current Assets

113,936,809,000

Fixed Assets

63,463,334,000

Net worth

82,468,843,000

Liabilities

94,931,300,000

Bank liabilities

33,678,889,000

The cash flow is

NORMAL

 

Legal Fillings

 The sources consulted record no detrimental legal or labor court information.

 

 

Rating

 

Local credit bureau gave a correct credit rate.

 

The company is in Good Standing. This means that all local and federal taxes were paid on due date.

 

 

 Final Opinion

 



 

The subject is a big size Colombian company.

 

It started its operations in 1985. Therefore, it has a very good experience in its field.

 

CI FARMACAPSULAS SA manufactures pharmaceutical capsules.

 

The company has operations national and internationally, as well.

 

It seems to have an adequate business structure, based on the information found regarding its size and commercial operations.

 

No specific adverse record has been found on the subject.

 

 


SUMMARY

 


FINANCIAL SUMMARY


DEBT COLLECTIONS AND PAYMENTS

Profitability

CORRECT

Public

NO

Indebtedness

LOW

Payments

REGULAR

Cash

NORMAL

 

 



APPENDIX

 

Comments

 

We have tried to contact the company but we were directed to a voicemail that stated the company has recently changed its "extensions". We dialed different numbers in order to reach a representative but we were directed to the same voicemail. We could not leave a message.

 


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.55.34

UK Pound

1

Rs.86.45

Euro

1

Rs.68.43

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.